Considering the significance of programmed death-ligand 1 (PD-L1) [23], tumor mutation burden (TMB) [24], and microsatellite instability (MSI) as important biomarkers for immunotherapy response [25], we assessed the correlation between PLEK2 expression and TMB/MSI across multiple cancer types. This evidence concerns the gene PLEK2 and neoplasm.